Sanofi-Aventis gets FDA OK for SarclisaSanofi-Aventis' Sarclisa works by helping certain cells in the immune system attack multiple myeloma cancer cells. Biohaven gets FDA nod for Nurtec ODTBiohaven's Nurtec ODT is a single quick-dissolving oral tablet for adult patients with acute migraine. Sun Pharma introduces Riomet ER Sun Pharma’s Riomet ER is the first and only liquid formulation of metformin for Type 2 diabetes patients. Seqirus gets FDA nod for Fluad Seqirus' Fluad Quadrivalent vaccine offers flu protection for adults 65 years old and older. FDA approves Lundbeck’s Vyepti Lundbeck’s Vyepti is the first and only intravenous preventive treatment for migraine. Sun Pharma rolls out Absorica LD Sun Pharma's Absorica LD features a special formulation of active ingredient isotretinoin meant to optimize absorption at a 20% lower dose. FDA approves Eagle's Pemfexy Eagle has exclusive rights to commercialize Pemfexy for four months beginning Feb. 1, 2022, with an uncapped entry into the market expected on April 1, 2022. FDA clears 1st treatment for peanut allergy in children The FDA has approved Palforzia, the first treatment for peanut allergy in children. Fresenius Kabi introduces Glucagon Emergency Kit Fresenius Kabi's glucagon emergency kit provides a treatment for severe hypoglycemia in pediatric and adult patients with diabetes. Seqirus gets FDA nod for Audenz The FDA has approved the first adjuvanted, cell-based Pandemic Influenza A (H5N1) vaccine. First Previous 29 30 31 32 33 Next Last
